Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation
Atrial fibrillation (AF) affects 1 in 4 individuals during their lifetime and continues
to increase in frequency and impact. Exercise intervention has established benefits to
improve AF symptoms and burden in clinical studies. However, lack of access to exercise
prog...
Age: 18 years - 66+
Gender: All
Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)
Sphere-9 VT EFS is a prospective, multi-center, non-randomized, unblinded feasibility
study. Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia due
to prior myocardial infarction will be enrolled and treated with the Sphere-9 Catheter
and A...
Age: 18 - 85 years
Gender: All
The Prevent Coronary Artery Disease Trial
Despite increasing evidence that exposure to cardiovascular risk factors (CVRF) at an early age increases the prevalence of subclinical atherosclerosis and is associated with a greater risk of cardiovascular events later in life, there is a lack of randomized trial evid...
Age: 30 - 50 years
Gender: All
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the
incidence of serious heart-related complications or prevent the worsening of kidney
function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and
Atheroscl...
Age: 45 years - 66+
Gender: All
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the
incidence of serious heart-related complications or prevent the worsening of kidney
function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and
Atheroscl...
Age: 45 years - 66+
Gender: All
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
This is a prospective, multi-center, open label, randomized control clinical trial
evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in
NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial).
The study contains of 5 arms:
...
Age: 18 years - 66+
Gender: All